On March 28, 2024 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place in San Diego, California, April 5-10, 2024 (Press release, Personalis, MAR 28, 2024, View Source [SID1234641600]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Personalis is excited to present data showing our ultra-sensitive MRD test, NeXT Personal, has the potential to find recurrent cancer earlier and monitor response in late-stage cancer patients receiving immunotherapy," said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

Personalis will be sharing progress with collaborative research findings as well as the latest clinical results related to NeXT Personal. Highlights include:

Mini-symposium (Liquid Biopsy): Ultra-sensitive ctDNA detection predicts response to immune checkpoint inhibition in advanced melanoma patients
Speaker: Dr. Christoffer Gebhardt
Date & Time: Tuesday, April 9, 2:55 PM – 3:10 PM
Location: Room 6 CF – Upper Level – Convention Center
ctDNA dynamics detected with NeXT Personal were predictive of patient response and outcomes in melanoma patients receiving immunotherapy; over a third of ctDNA detections were in the ultra-sensitive range (<100 PPM) in advanced melanoma patients.

Abstract Title: Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune-checkpoint blockade
Session Date & Time: Sunday, Apr 7, 2024 1:30 PM – 5:00 PM
Location: Poster Section 40, Number 17
Abstract Number: 976
Changes in ctDNA levels detected with NeXT Personal predicted therapy response and overall survival in late-stage hepatocellular carcinoma patients treated with a personalized cancer vaccine.

Abstract Title: Analytic validation of an ultra-sensitive tumor-informed circulating tumor DNA assay based on whole genome sequencing
Session Date & Time: Tuesday, Apr 9, 2024 9:00 AM – 12:30 PM
Location: Poster Section 40, Number 21
Abstract Number: 5034
Analytical validation of NeXT Personal demonstrated ultra-sensitivity down to 1 PPM of ctDNA and high specificity, reinforcing the potential to detect recurrent cancer earlier.

Abstract Title: Detection of MRD assessment with the Personalis NeXT Personal assay using MATRIX plasma-in-plasma contrived samples
Session Date & Time: Tuesday, Apr 9, 2024 1:30 PM – 5:00 PM
Location: Poster Section 31, Number 20
Abstract Number: 6094
Biopharma partner blinded study showed NeXT Personal’s ability to detect ultra-low levels of ctDNA.